Evidence map›Paper›PMID 39984462›Full record

ArticleNature communications2025

Early Alzheimer's Disease with frequent neuritic plaques harbors neocortical tau seeds distinct from primary age-related tauopathy.

Danielle F Browne, Denis S Smirnov, David G Coughlin, Iris Peng, Heidi G Standke, Yongya Kim, Donald P Pizzo, Alexandra Unapanta, Thea Andreasson, Annie Hiniker and 1 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Primary age-related tauopathy.Acta neuropathologica · 2025
    Review
  7. Hippocampal tau distribution in primary age-related tauopathy: The Vantaa 85+ Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Danielle F Browne *Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, 44106, OH, USA.ORCID http://orcid.org/0000-0002-7235-4508
Denis S Smirnov *Department of Neurosciences, University of California San Diego, La Jolla, CA, 92037, USA.
David G CoughlinDepartment of Neurosciences, University of California San Diego, La Jolla, CA, 92037, USA.ORCID http://orcid.org/0000-0003-4111-0102
Iris PengDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, 44106, OH, USA.
Heidi G StandkeDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, 44106, OH, USA.
Yongya KimDepartment of Neurosciences, University of California San Diego, La Jolla, CA, 92037, USA.
Donald P PizzoDepartment of Pathology, University of California San Diego, La Jolla, 92037, CA, USA.
Alexandra UnapantaDepartment of Pathology, University of California San Diego, La Jolla, 92037, CA, USA.
Thea AndreassonDepartment of Neurosciences, University of California San Diego, La Jolla, CA, 92037, USA.
Annie HinikerDepartment of Pathology, University of California San Diego, La Jolla, 92037, CA, USA. ahiniker@usc.edu.ORCID http://orcid.org/0000-0002-0055-6610
Allison KrausDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, 44106, OH, USA. allison.kraus@case.edu.ORCID http://orcid.org/0000-0001-8477-0894

Funding

UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Steven Dyal Edland · 2019 to 2026
$34.9M
Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer's DiseaseP01AG052350 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Daniel A Nation, ARTHUR W TOGA · 2016 to 2026
$28.4M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
Translational and Therapeutics CoreP30AG072959 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI JAGAN AYYAPPAN PILLAI · 2021 to 2026
$23.9M
Peripheral Tissue Biomarker for Premorten Diagnosis of Lewy Body DementiaR01NS118760 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CHEN, SHU G., KRAUS, ALLISON L · 2020 to 2025
$7.4M
Medical Scientist Training Program at Case Western Reserve UniversityT32GM152319 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI Heather Broihier, Alex Yee-Chen Huang · 2024 to 2026
$5.1M
Skin biomarkers for diagnosing and characterizing AD and ADRDR01AG067607 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI CHEN, SHU G., KRAUS, ALLISON L · 2021 to 2025
$3.8M
Targeting Proteostatic Mechanisms to Inhibit LRRK2-Mediated Neurodegeneration and NeuropathologyR01NS135607 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Annie E Hiniker · 2023 to 2026
$2.8M
Training in Neurodegenerative DiseasesT32NS077888 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI Xiongwei Zhu · 2013 to 2026
$1.8M
Pathological and cognitive correlations of real time quaking induced conversion in LBD and ADK23NS120038 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI COUGHLIN, DAVID G · 2021 to 2025
$828k
Repetition Priming Deficits and Locus Coeruleus Dysfunction in Alzheimer's DiseaseF30AG063440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SMIRNOV, DENIS · 2019 to 2022
$179k
NIA NIH HHS F30 AG063440NIA NIH HHS P01 AG052350NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG072959NIA NIH HHS R01 AG067607NIGMS NIH HHS T32 GM152319NINDS NIH HHS K23 NS120038NINDS NIH HHS R01 NS118760NINDS NIH HHS R01 NS135607NINDS NIH HHS T32 NS077888
6 · The paper itself

Abstract

Tau neurofibrillary tangles (NFTs) in the presence of amyloid-β (Aβ) plaques are required for the diagnosis of Alzheimer's Disease (AD) and closely track with cognitive impairment, yet cognitively normal aged individuals frequently exhibit NFTs arising from tau seed accumulation. This may suggest that not all tau species are equally pathogenic and raises the question of whether unidentified tau modifications augment tau seeding activity and neurodegeneration in AD. We investigated how biochemical modifications of tau relate to clinicopathological outcomes in a cohort of 38 patients with Braak-matched AD neuropathologic change (ADNC) or primary age-related tauopathy (PART), a 3R/4R tauopathy with identical tau filament core structure to ADNC but with little to no Aβ deposition. We comprehensively measured tau histologic density, seeding activity using real-time quaking induced conversion (RT-QuIC) seed amplification assays, and select post-translational modifications (PTMs) (i.e. pT217, pS202/T205, & C-terminal epitopes) in hippocampus and neocortex. Even in cases without overt neocortical tau neuropathology, substantial hippocampal and neocortical tau seeding occurred in both PART and ADNC and predicted region-specific cognitive performance and longitudinal decline. Notably, tau seeding and PTM profiles were associated with Aβ neuritic plaque density and differentiated ADNC from PART in neocortex. Our data indicate that tau seed modifications meaningfully relate to disease trajectory, potentially explaining the more severe cognitive dysfunction observed in late-stage AD versus PART.

Indexed as

Alzheimer DiseaseNeocortexPlaque, AmyloidTauopathiestau ProteinsAgedAged, 80 and overAmyloid beta-PeptidesFemaleHippocampusHumansMaleMiddle AgedNeurofibrillary TanglesProtein Processing, Post-TranslationalAmyloid beta-Peptidestau Proteins

Identifiers

PMID39984462
PMCPMC11845591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.